1. Pink Sheet

New Expert Group To Drive European Pharmacopoeial Standards For mRNA Vaccines

 
• By Vibha Sharma

With growing interest in expanding the use of mRNA vaccines beyond COVID-19, the European Pharmacopoeia Commission has announced a new working party whose first task will be to develop a consolidated strategy on future standards for these vaccines and their components.

Concept of mRNA vaccines on wooden cubes
Companies are exploring the use of mRNA vaccine technology beyond COVID‐19 • Source: Shutterstock

The successful deployment of mRNA vaccines against COVID-19 and their potential to prevent other infections and diseases has prompted the European Pharmacopoeia (PhEur) Commission to establish a new working party to help support this emerging field.

Quality standards developed by the new mRNA vaccines (mRNAVAC) working party will be included in the PhEur, said the European Directorate for the Quality of Medicines

More from Vaccines

More from Pink Sheet